Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Lyell Immunopharma's FCF Margin % or its related term are showing as below:
LYEL'
s FCF Margin % Range Over the Past 10 Years
Min: -433609.68 Med: -2737.94 Max: 3565.75
Current: -433609.68
During the past 7 years, the highest FCF Margin % of Lyell Immunopharma was 3565.75%. The lowest was -433609.68%. And the median was -2737.94%.
LYEL's FCF Margin % is ranked worse than 99.58% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs LYEL: -433609.68
Lyell Immunopharma FCF Margin % Related Terms
Lyell Immunopharma FCF Margin % Historical Data
* Premium members only.
The historical data trend for Lyell Immunopharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lyell Immunopharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyell Immunopharma FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Lyell Immunopharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyell Immunopharma (LYEL) has a FCF Margin % of -1,929,950.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Lyell Immunopharma and its competitors. According to the industry distribution chart, Lyell Immunopharma ranks #946 out of 950 companies in the Biotechnology industry, placing it in the top 99.6%.
Is Lyell Immunopharma's FCF Margin % too high?
Lyell Immunopharma's current FCF Margin % is -1,929,950.00%. Based on the distribution chart, Lyell Immunopharma ranks #946 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lyell Immunopharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lyell Immunopharma's FCF Margin % compare to ALXO and ARMP?
According to the Biotechnology industry distribution chart, Lyell Immunopharma ranks #946 out of 950 companies for FCF Margin %. This places Lyell Immunopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Lyell Immunopharma and its competitors. Lyell Immunopharma's current FCF Margin % is -1,929,950.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyell Immunopharma stock overvalued right now?
Based on GuruFocus' analysis, Lyell Immunopharma (LYEL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.26, compared to a current price of $13.19 — trading 150.8% above its estimated fair value. The current FCF Margin % is -1,929,950.00%. Lyell Immunopharma's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Lyell Immunopharma (LYEL), the current FCF Margin % is -1,929,950.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyell Immunopharma (LYEL) Overvalued in 2026?
Based on GuruFocus' analysis, Lyell Immunopharma stock appears to be overvalued.
The current stock price of $13.19 is trading 150.8% above its estimated GF Value™ of $5.26.
GuruFocus considers Lyell Immunopharma to be Significantly Overvalued.
Key valuation signals for LYEL:
FCF Margin %: -1,929,950.00%
GF Value™: $5.26 vs. price of $13.19 (150.8% above fair value)
No single metric tells the full story. See the LYEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
55GF Score
Get the complete analysis for LYEL
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LYEL has been successfully added to your 
